Skip to main content
OpenTrials
Completed

NCT Number: NCT05200598

Cardiovascular Risk Predictors in Patients With Psoriasis

The investigators are planning to find the right modification of traditionally used risk scores (PASI, DLQI) in patients with psoriasis of different severity to guide the treatment that could potentially extend life, improve cardiovascular outcomes and quality of life in patients with psoriasis and cardiovascular risk factors in a prospective observational study. The traditionally excluded groups of older patients with diabetes mellitus, decreased kidney function and those with potentially worse prognosis are going to be included in the study. As it's known, the number of those patients is on the rise each year and require a close attention of multidisciplinary teams.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Cardiovascular Diseases Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University Clinical Hospital #2

Moscow, 119991, Russia

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age over 18 years
  • Written informed consent of the patient to participate in the study

Exclusion criteria

  • Age under 18
  • Pregnancy, lactation
  • Very high cardiovascular risk
  • Life-threatening, independently influencing prognosis and disabling diseases,
  • Mental disorders that do not allow to give informed consent or answer questions adequately
  • Refuse of the patient to participate in the study

Treatment and study plan

Primary outcomes

  1. SCORE2-OP risk (Systematic COronary Risk Evaluation2- Older Person)

    Time frame: 1 year

    Increased cardiovascular risk over the follow-up period (from low to very high)

Secondary outcomes

  1. Overall mortality

    Time frame: 1 year

    Number of deaths due to all reasons

  2. Cardiovascular mortality

    Time frame: 1 year

    Number of deaths due to cardiovascular reasons

  3. Progression of psoriasis (PASI)

    Time frame: 1 year

    Progression of severity of psoriasis according to PASI (The Psoriasis Area and Severity Index - 0 to 4, none to very severe) score

  4. Quality of life (DLQI score)

    Time frame: 1 year

    Impact on quality of life by DLQI (Dermatology Life Quality Index - 0 to 30, no to extremely large impact) score

  5. Hospitalization due to cardiovascular reasons

    Time frame: 1 year

    Number of patients hospitalized due to cardiovascular reasons

Sponsors and collaborators

Lead sponsor

I.M. Sechenov First Moscow State Medical University

Other

Registry information

Important dates

Study start
2021
Primary completion
2023
Study completion
2024
First posted
Jan 21, 2022
Registry last updated
Oct 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.